title: Nitric oxide and histone deacetylases: A new relationship between old molecules.
abstract: Histone deacetylases (HDACs) are enzymes that catalyze the removal of acetyl groups from a range of nuclear and cytoplasmic proteins. Recently, we described a novel route to neurotrophin-dependent gene activation in neurons, which requires the S-nitrosylation of nuclear HDAC2 by the gaseous molecule nitric oxide (NO).1 We have further investigated the NO-dependent regulation of HDACs in neurons. Using a fluorogenic deacetylation assay, we show that NO decreases the enzymatic activity of a subgroup of neuronal HDACs in vitro and that this inhibition is not due to damaging modifications such as oxidation or tyrosine nitration. The neuronal HDACs whose catalytic activity is inhibited by NO are entirely those that are localized in the cytoplasm. These observations support and extend the concept that nitric oxide is a key regulator of HDAC function in mammalian neurons.
authors.affiliation: MRC Laboratory for Molecular and Cell Biology; and Department of Neuroscience, Physiology and Pharmacology; University College London; London UK.
authors.forename: P Marc D
authors.initials: PM
authors.lastname: Watson
authors.forename: Antonella
authors.initials: A
authors.lastname: Riccio
references.citation: J Cell Biochem. 2008 Aug 1;104(5):1541-52
references.pmid: 18425769
references.citation: Oncogene. 2007 Aug 13;26(37):5420-32
references.pmid: 17694083
references.citation: Annu Rev Physiol. 2009;71:451-64
references.pmid: 18817512
references.citation: Chem Biol. 2003 Jan;10(1):61-8
references.pmid: 12573699
references.citation: Nat Rev Mol Cell Biol. 2008 Mar;9(3):206-18
references.pmid: 18292778
references.citation: Curr Opin Pharmacol. 2008 Feb;8(1):57-64
references.pmid: 18206423
references.citation: Nat Rev Mol Cell Biol. 2005 Feb;6(2):150-66
references.pmid: 15688001
references.citation: Clin Exp Metastasis. 2008;25(2):183-9
references.pmid: 18058245
references.citation: Mol Cell. 2008 Aug 22;31(4):449-461
references.pmid: 18722172
references.citation: Gene. 2005 Dec 19;363:15-23
references.pmid: 16289629
references.citation: Expert Opin Drug Saf. 2008 Jan;7(1):53-67
references.pmid: 18171314
references.citation: Biochem J. 2007 May 15;404(1):1-13
references.pmid: 17447894
references.citation: Nat Rev Drug Discov. 2008 Oct;7(10):854-68
references.pmid: 18827828
references.citation: Biochem J. 2003 Mar 15;370(Pt 3):737-49
references.pmid: 12429021
references.citation: Mol Cell. 2006 Jan 20;21(2):283-94
references.pmid: 16427017
references.citation: Biochem Biophys Res Commun. 2004 Feb 27;315(1):240-5
references.pmid: 15013452
references.citation: Expert Opin Investig Drugs. 2008 Feb;17(2):169-84
references.pmid: 18230051
references.citation: J Mol Biol. 2004 Apr 16;338(1):17-31
references.pmid: 15050820
references.citation: Trends Cell Biol. 2008 Jun;18(6):291-7
references.pmid: 18472263
references.citation: J Cell Biochem. 2004 Sep 1;93(1):57-67
references.pmid: 15352162
references.citation: Eur J Neurosci. 2008 Jun;27(11):2783-802
references.pmid: 18588525
references.citation: Oncogene. 2007 Aug 13;26(37):5468-76
references.pmid: 17694087
references.citation: Nature. 2008 Sep 18;455(7211):411-5
references.pmid: 18754010
references.citation: Curr Opin Pharmacol. 2006 Aug;6(4):369-75
references.pmid: 16781195
references.citation: Biochimie. 2008 Feb;90(2):306-12
references.pmid: 17681659
references.citation: Nat Rev Neurosci. 2007 Oct;8(10):766-75
references.pmid: 17882254